Clinical Trial Update: Cardiometabolic Effects of Dapagliflozin in Heart Failure With Reduced or Mildly Reduced Ejection Fraction [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the cardiometabolic effects of dapagliflozin in heart failure with reduced or mildly reduced ejection fraction.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Mildly Reduced Ejection Fraction
• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Heart Failure, Reduced Ejection Fraction | Phase 2 | Status: UNKNOWN